Synonyms: ASP-1517 | ASP1517 | Evrenzo® | FG-4592 | FG4592
roxadustat is an approved drug (EMA (2021))
Compound class:
Synthetic organic
Comment: Roxadustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD) [2]. It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients.
|
|
References |
1. Bouchie A. (2013)
First-in-class anemia drug takes aim at Amgen's dominion. Nat Biotechnol, 31 (11): 948-9. [PMID:24213751] |
2. Forristal CE, Levesque JP. (2014)
Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cells Transl Med, 3 (2): 135-40. [PMID:24371328] |
3. Joharapurkar AA, Pandya VB, Patel VJ, Desai RC, Jain MR. (2018)
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J Med Chem, 61 (16): 6964-6982. [PMID:29712435] |
4. Liu C, Jursa T, Aschner M, Smith DR, Mukhopadhyay S. (2021)
Up-regulation of the manganese transporter SLC30A10 by hypoxia-inducible factors defines a homeostatic response to manganese toxicity. Proc Natl Acad Sci U S A, 118 (35). DOI: 10.1073/pnas.2107673118 [PMID:34446561] |